Skip to main content
SpringerLink
Log in

Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F (1994) False-positives in spontaneous reporting: should we worry about them. Br J Clin Pharmacol 38(5):401–404

    CAS  PubMed  Google Scholar 

  2. Cox AR, Marriott JF, Wilson KA, Ferner RE (2004) Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. J Clin Pharm Ther 29:31–35

    CAS  PubMed  Google Scholar 

  3. Hauben M, Reich L, Chung S (2004) Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. Eur J Clin Pharmacol 60(10):747–750

    PubMed  Google Scholar 

  4. Kubota K, Koide D, Hirai T (2004) Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf 13:387–394

    PubMed  Google Scholar 

  5. Layton D, Heeley E, Shakir SAW (2004) Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data. J Clin Pharm Ther 29:171–178

    CAS  PubMed  Google Scholar 

  6. Meyboom RH, Egberts AC, Edwards IR, Hekster YA, De Koning FHP, Gribnau FWJ (1997) Principles of signal detection in pharmacovigilance. Drug Saf 16(6):355–365

    CAS  PubMed  Google Scholar 

  7. Stahl M, Edwards R, Bowring G, Kiuru A, Lindquist M (2003) Assessing the impact of drug safety signals from the WHO database presented in ‘SIGNAL’: results from a questionnaire of national pharmacovigilance centers. Drug Saf 26(10):721–727

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Director, Risk Management Strategy, Pfizer Inc., New York, NY, USA

    Manfred Hauben & Lester Reich

  2. Department of Medicine, New York University School of Medicine, New York, NY, USA

    Manfred Hauben

  3. Departments of Pharmacology and Community and Preventive Medicine, New York Medical College, Valhalla, NY, USA

    Manfred Hauben

Authors
  1. Manfred Hauben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lester Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lester Reich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hauben, M., Reich, L. Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use. Eur J Clin Pharmacol 61, 479–480 (2005). https://doi.org/10.1007/s00228-005-0951-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0951-4

Keywords

Search

Navigation